AZ Explores Orphan Diseases To Boost Fasenra Growth
The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.
The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.